Trapeze Asset Management

Trapeze Therapeutics is a privately-held biotechnology company focused on developing next-generation cancer therapies using an engineered protein platform. Co-founded by Stanford Professor Jennifer Cochran, the company leverages "knottins" (cystine-knot miniproteins) to create targeted delivery systems for immunostimulants and to enhance the efficacy of CAR-T cell therapies. Its lead research includes PIP-CpG, a targeted TLR9 agonist that localizes to tumors via integrin binding, and engineered CD47 variants designed to protect CAR-T cells from macrophage-mediated clearance. The company's technology aims to transform the immune landscape of solid tumors by enabling synergistic effects between the innate and adaptive immune systems.